Biotherapeutic peptides and proteins are often PEGylated (covalently bonded to polyethylene glycol polymers) to improve bioavailability, reduce immunogenicity, and extend circulating half-life (1). Achieving the desired properties for each application depends on optimizing the number and site of polymers attached, chain length, and the degree of chain branching.
